Gastroenteritis News and Research

RSS

Gastroenteritis (also known as gastro, gastric flu, and stomach flu) refers to inflammation of the gastrointestinal tract, involving both the stomach and the small intestine and resulting in acute diarrhea. The inflammation is caused most often by infection with certain viruses, less often by bacteria or their toxins, parasites, or adverse reaction to something in the diet or medication.

Cheap and accessible methods for genome sequencing will help tackle future pandemics

A worldwide consortium of scientists, led by the Earlham Institute and the University of Liverpool in the UK, mark a significant milestone in equipping researchers in low- and middle-income countries (LMICs) with cheap and accessible methods for sequencing large collections of bacterial pathogens - at a cost of less than $10USD per genome.

21 Dec 2021

A canine coronavirus zoonotic spillover and tropism shift

...

21 Nov 2021

Structure of human-infecting canine coronavirus HuPn-2018 spike glycoprotein

As CCoV-HuPn-2018 has been recently isolated in a child's respiratory swab, researchers from the University Of Washington have been examining the structure of the virus.

28 Oct 2021

Study findings may lead to new treatments to fight deadly C. difficile infections

A University of California, Irvine-led study suggests that the glucosyltransferase domain (GTD) is an ideal molecular target for therapeutic interventions for Clostridioides difficile infection (CDI). These findings may lead to new treatments to fight this deadly disease.

22 Oct 2021

Researchers plan review of cruise ship COVID-19 outbreaks

Researchers plan to provide a comprehensive summary of data from cruise ship outbreaks and explore models of transmission at sea.

18 Oct 2021

UK Sepsis Trust calls for people to better understand the signs and symptoms of sepsis

This World Sepsis Day, the UK Sepsis Trust is calling for people to better understand the signs and symptoms of sepsis and recognize it as a medical emergency, in order to reduce the risk of death and mitigate against the very real long-term health effects of post-sepsis syndrome.

15 Sep 2021

Diagnosis of viral infections using micro and nanoscale technologies

In a recent study, the authors provide a review on both micro- and nanoscale technologies that advanced the diagnosis of viral diseases.

3 Aug 2021

Human coronaviruses need organic materials to transfer efficiently between surfaces

This study, published in the journal Viruses, indicated that human coronaviruses do not transfer effectively from contaminated hands to contact surfaces without the presence of any organic material.

21 Jul 2021

Redhill Biopharma announces completion of Phase 2/3 COVID-19 study of oral opaganib

RedHill Biopharma Ltd., a specialty pharma company that is a leader in the development of novel oral therapies for COVID-19, today announced that all treatment and follow-up has now been completed in the 475-patient global Phase 2/3 study with opaganib (ABC294640) in patients hospitalized with severe COVID-19 pneumonia (NCT04467840). Top-line results are expected in the coming weeks.

20 Jul 2021

Researchers isolate human monoclonal antibodies that may neutralize several norovirus variants

Researchers at Vanderbilt University Medical Center and the Baylor College of Medicine in Houston, Texas, have taken a big step toward developing targeted treatments and vaccines against a family of viruses that attacks the gastrointestinal tract.

16 Jul 2021

SARS-CoV N protein elicits production of IFN-β by provoking ubiquitination of RIG-I, finds study

A recent study published in Frontiers in Immunology focuses on the roles of the SADS-CoV N protein in IFN suppression during infection.

23 Jun 2021

RedHill presents positive Phase 2 results for oral opaganib in patients with COVID-19 pneumonia

RedHill Biopharma Ltd., a specialty biopharmaceutical company, today announced presentation of the positive Phase 2 safety and efficacy data for oral opaganib (Yeliva®, ABC294640) in hospitalized patients with COVID-19 pneumonia at the World Microbe Forum (WMF) 2021 (poster #: 5574).

21 Jun 2021

Study paves the way for development of new therapeutics for C. difficile infection

A new study paves the way for the development of next generation therapeutics for the prevention and treatment of Clostridioides difficile infection (CDI), the most frequent cause of healthcare-acquired gastrointestinal infections and death in developed countries.

18 Jun 2021

Redhill Biopharma announces completion of enrollment for oral opaganib phase 2/3 COVID-19 study

RedHill Biopharma Ltd., a specialty biopharmaceutical company, today announced that it has completed enrollment and randomized the last patient in the global Phase 2/3 study with opaganib (Yeliva, ABC294640) in patients hospitalized with severe COVID-19 pneumonia (NCT04467840).

7 Jun 2021

Weight loss drug Wegovy approved by FDA

The U.S. Food and Drug Administration (FDA) has approved Wegovy (semaglutide) injection (2.4 mg once weekly) as a chronic weight management treatment in obese or overweight adults with a weight-related condition (such as high blood pressure, type 2 diabetes, or high cholesterol), when used along with calorie restriction and physical activity. Wegovy, is a more potent version of Novo Nordisk's diabetes drug semaglutide.

4 Jun 2021

Salmonella bacteria colonize the gut using intestinal epithelial cells

The immune system's attempt to eliminate Salmonella bacteria from the gastrointestinal (GI) tract instead facilitates colonization of the intestinal tract and fecal shedding, according to National Institutes of Health scientists.

26 May 2021

Nanotechnology and COVID-19 diagnosis and treatment

The development of nano-biosensors and nanoparticle-based vaccines and medicines has opened a new path toward better management of the coronavirus disease 2019 (COVID-19) pandemic. In a recently published article in the journal ACS Biomaterials Science & Engineering, scientists have reviewed recent advancements in nanotechnology-based diagnostic and therapeutic interventions against human coronaviruses.

17 May 2021

Study: Norovirus clusters are resistant to detergent and ultraviolet disinfection

Clusters of a virus known to cause stomach flu are resistant to detergent and ultraviolet disinfection, according to new research co-led by Danmeng Shuai, Ph.D., an associate professor of civil and environmental engineering at the George Washington University and Nihal Altan-Bonnet, Ph.D., a senior investigator and the head of the Laboratory of Host-Pathogen Dynamics at the National Heart, Lung, and Blood Institute, part of the National Institutes of Health.

16 Apr 2021

RedHill provides opaganib treatment under compassionate use exemption for Swiss COVID-19 patients

RedHill Biopharma Ltd., a specialty biopharmaceutical company, today announced that it has acted on a request to provide opaganib treatment on an outpatient basis under compassionate use exemption for several Swiss patients suffering from COVID-19 pneumonia.

22 Mar 2021

Apoptosis is an important mediator of pathogenesis in animal coronavirus infection

A new paper in the journal Life presents an early review of the viral factors involved in initiating and effecting apoptosis within infected cells.

8 Mar 2021